/ /

CLINICAL

Lifitegrast data support dry eye efficacy over placebo dropsLifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
Protein agent may change approach to treating dry eye, inflammationRecombinant human lubricin showed potential as a new therapeutic approach to the management of dry eye disease in a small clinical trial. Compared with sodium hyaluronate, lubricin (Lubris BioPharma), significantly improved both signs and symptoms of moderate dry eye after two weeks of treatment.
Exploring off-label, investigational approaches for allergic conjunctivitisSeasonal and perennial allergic conjunctivitis are common conditions that are not always well-controlled with conventional therapy. Alternative approaches and novel investigational treatments are discussed.
Novel topical peptide for dry eye tackles underlying cause of diseaseA phase I/II trial enrolling patients with Sjögrens syndrome dry eye will be investigating  a synthetic fragment of a naturally occurring tear glycoprotein. Findings from extensive laboratory and preclinical research suggest that it is a promising novel therapy.
Novel neurostimulator device uses nasal cavities to stimulate tearsChronic dry eye disease (DED) affects more than 25 million people and to date the only pharmacologic therapies are topical or involve punctal plugs. Results from two studies wth a neurostimulator indicate there may be a new pathway to upregulate the body’s tear system.
Non-invasive punctal plug delivery system offers a host of positive performance characteristics
Non-invasive punctal plug delivery system offers a host of positive performance characteristicsA silicone punctal plug-based delivery system for ophthalmic medications (Evolute, Mati Therapeutics) provides precisely controlled medication release into the tear film and has been associated with positive results in initial clinical testing.
Bimatoprost insert offers noninvasive platform for early glaucoma patients A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.
The case of the blurred disc marginsA 16-year-old female was scheduled for her periodic ophthalmic evaluation to update her spectacle lens prescription. At the visit, she reported a history of migraines, but the remainder of her personal and family medical history was non-contributory. She took no medications and had a history of low hyperopic refractive correction.
7 tips for safer lens wear with cosmeticsA few tips regarding wearing cosmetics and contact lens wear can help our patients wear their lenses with more comfort.
6 challenges when changing from a group to private practice
6 challenges when changing from a group to private practiceA little over 18 months ago, I decided to follow my passion and take a leap of faith changing my career. I went from a bustling MD/OD group practice to a private group OD practice and launched the Dry Eye Center of Pennsylvania (PA).